 The pure S-enantiomer structure of landiolol is believed to develop less hypotensive side effects in comparison to other β-blockers.This has a positive impact on the treatment of patients when reduction of heart rate without decrease in arterial blood pressure is desired.Landiolol was developed by modifying the chemical structure of esmolol to produce a compound with a higher rate of cardioselectivity and a greater potency without increasing its duration of action.